SCHEMBL24762008

SCHEMBL24762008

COC(=O)CNS(=O)(=O)c1ccc(Br)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.71
SMN1; SMN2 Q16637 2/20 0.71
GAA P10253 2/20 0.71
KDM4E B2RXH2 2/20 0.71
NPC1 O15118 1/20 0.71
HPGD P15428 1/20 0.71
RAB9A P51151 1/20 0.71
MMP2 P08253 3/20 0.62
MMP9 P14780 3/20 0.62
MMP1 P03956 2/20 0.62
MMP13 P45452 2/20 0.62
MMP3 P08254 1/20 0.62
MMP7 P09237 1/20 0.62
MMP14 P50281 1/20 0.53
ADAM17 P78536 1/20 0.53
IDO1 P14902 1/20 0.52
MEP1B Q16820 1/20 0.51
SIGMAR1 Q99720 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7261912 0.86 ALDH1A1 (0.64) ALDH1A1SMN1; SMN2GAAKDM4ENPC1
SCHEMBL570839 0.85 ALDH1A1 (0.73) ALDH1A1SMN1; SMN2GAAKDM4ENPC1
SCHEMBL19450297 0.84 MMP2 (0.56) ALDH1A1SMN1; SMN2GAAKDM4ENPC1
SCHEMBL18498935 0.84 IDO1 (0.56) ALDH1A1SMN1; SMN2GAAKDM4ENPC1
SCHEMBL8131965 0.84 ALDH1A1 (0.77) ALDH1A1SMN1; SMN2GAAKDM4ENPC1
SCHEMBL28677877 0.83 KDM4E (0.71) ALDH1A1SMN1; SMN2GAAKDM4ENPC1
SCHEMBL7383813 0.83 ALDH1A1 (0.71) ALDH1A1SMN1; SMN2GAAKDM4ENPC1
SCHEMBL24762900 0.83 ALDH1A1 (0.71) ALDH1A1SMN1; SMN2GAAKDM4ENPC1
SCHEMBL24762895 0.83 ALDH1A1 (0.71) ALDH1A1SMN1; SMN2GAAKDM4ENPC1
SCHEMBL3239227 0.83 ALDH1A1 (0.71) ALDH1A1SMN1; SMN2GAAKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240190821-A1 SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF TRIANA BIOMEDICINES INC (US) 2024-06-13 US disclosed
WO-2022169755-A1 SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL) BENZENESULFONAMIDES AND USES THEREOF TRIANA BIOMEDICINES, INC. (US) 2022-08-11 WO disclosed
WO-2022169755-A1 SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL) BENZENESULFONAMIDES AND USES THEREOF TRIANA BIOMEDICINES, INC. (US) 2022-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240190821-A1 SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF PACSIN2, TPX2, PRSS12 ALDH1A1 3608/4885SMN1; SMN2 523/4885GAA 798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.